Gilead steals a march for hepatitis C drug application

The European Medicines Agency will provide an accelerated review of the treatment combined with ribavirin, which is shaping up as the first all-oral hepatitis C regimen up for a regulatory decision.

---

European Medicines Agency Validates Gilead Sciences, Inc.’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys…

---

Gilead Sciences, Inc. to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the…

---

Experimental Gilead Sciences, Inc. Drug Effective in Early-Stage Leukemia Trial

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had ret…

---